



Tumor Specific Antigens

Antibodies Targeting Tumor Specific Antigens

bioxcell.com



Tumor Specific Antigens

Antigen	Reactivity	Application	Clone	Catalog Number	Isotype Control
CA19-9	human	IHCP, IF, FC	116-NS-19-9	BE0355	BE0083
CD19	human	FC, Functional assay, IF	4G7	BE0281	BE0083
CD19	mouse	<i>in vivo</i> B cell depletion, <i>in vivo</i> CD19 neutralization, <i>in vitro</i> B cell negative selection, FC	1D3	BE0150	BE0089
CD71 (TfR1)	human	FC, IHC-F	OKT9	BE0023	BE0083
CD71 (TfR1)	human	WB, IP, FC	5E9C11	BE0343	BE0083
CD71 (TfR1)	mouse	<i>in vivo</i> depletion of CD71+ cells	R17 217.1.3/T1B-219	BP0175	BP0089
CD71 (TfR1)	mouse	<i>in vivo</i> depletion of CD71+ cells, IF, IHC-F, WB	8D3	BP0329	BP0089
CD71 (TfR1)	rat/mouse	Targeted drug delivery to the brain, IHC-F, FC	OX-26	BE0331	BE0085
CD172a (SIRPα)	mouse	<i>in vivo</i> and <i>in vitro</i> SIRPα blocking	P84	BE0322	BE0088
CD200 (OX2)	mouse	<i>in vivo</i> and <i>in vitro</i> CD200 blockade, IHCF, IF, FC	OX-90	BE0299	BE0089
CD220 (insulin receptor)	human	WB	IR 83-22	BE0338	BE0083
CD326 (EpCAM)	mouse	IHCF, IF, FC, WB	G8.8	BE0346	BE0089
CEACAM 1/3/5/6/8	human	WB, ELISA, IF, IHCP, FC	6G5j	BE0362	BE0083
CEACAM7	human	WB, ELISA, IP, IHC, FC	P3-7B	BE0363	BE0083
c-Kit (CD117)	mouse	<i>in vivo</i> mast cell depletion, <i>in vivo</i> c-Kit+ cell depletion, <i>in vitro</i> c-Kit neutralization, IP, FC	ACK2	BE0293	BE0090
E-Cadherin (CD324)	mouse	<i>in vivo</i> and <i>in vitro</i> E-Cadherin neutralization, IF, IP, WB	DECMA-1	BE0352	BE0088
EGFR	human	<i>in vitro</i> EGFR blockade, <i>in vivo</i> EGFR blockade in xenografts, Functional assay, WB, IP, IHCP, IF, FC	528	BE0279	BE0085
EGFR	human	<i>in vitro</i> EGFR blockade, <i>in vivo</i> EGFR blockade in xenografts, Functional assay, WB	225	BE0278	BE0083
EGFR	human	<i>in vivo</i> EGFR blockade in xenografts, <i>in vitro</i> EGFR blockade, IP	425	BE0375	BE0085
EGFR	human	EGFR blockade, ELISA, FC	Cetuximab	SIM0002	BP0297
EphA2	human	IHCP, Functional assay, IP	B2D6	BE0341	BE0086
Ganglioside GD2	human	<i>in vitro</i> induction of apoptosis in GD2+ cells, <i>in vivo</i> inhibition of GD2+ tumor cell growth	14G2a	BE0318	BE0085
HER2	human	FC, ELISA, IHC, WB	Trastuzumab	SIM0005	BP0297
HER2	human/rat	<i>in vivo</i> and <i>in vitro</i> HER2 inhibition, IP, IF, FC	7.16.4	BE0277	BE0085
IL-27 p28	mouse	<i>in vivo</i> and <i>in vitro</i> IL-27 p28 neutralization, FC	MM27.7B1	BE0326	BE0085
LRP1 (CD91)	mouse/human/rat	WB, IF, IP	11H4	BE0333	BE0083
MUC1 (CD227)	human	<i>in vivo</i> administration in mouse xenograft models, <i>in vitro</i> cell cytotoxicity assay, IHCP, IF, WB	C595 (NCRC48)	BE0336	BE0093
PD-L1	mouse	<i>in vivo</i> PD-L1 blockade, IF, IHCF, FC, WB	10F.9G2	BP0101	BP0090
PrP (prion protein)	mouse/human	<i>in vivo</i> PrP blocking, WB	TW1	BE0350	BE0085
VEGFR-2	mouse	<i>in vivo</i> and <i>in vitro</i> blocking of VEGF/VEGFR-2 signaling, WB	DC101	BP0060	BP0088
VLDL-R	mouse/rat/bovine	WB	IgG-6A6	BE0345	BE0083

IF Immunofluorescence | IHC-F Immunohistochemistry (frozen) | IHC-P Immunohistochemistry (paraffin) | WB Western blot | IP Immunoprecipitation | FC Flow cytometry (requires fluochrome conjugation)

For over 25 years, scientists have trusted Bio X Cell as their go-to source for *in vivo* functional grade antibodies. This is reflected in over 15,000 peer-reviewed publications citing Bio X Cell products. We understand this responsibility is of paramount importance and remain committed to producing antibodies of unparalleled quality and consistency, enabling our partners around the globe to accelerate research and discoveries.

Bio X Cell
 bioxcell.com | 1.866.787.3444
 customerservice@bioxcell.com

Conditions: For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.
 Bio X Cell, Bio X Cell Logo and all other trademarks are the property of Bio X Cell © 2022 Bio X Cell

